Fig 1: LIMS2 inhibited OS cell growth and migration. U-2OS and Saos-2 cells divided into control, NC and LIMS2 groups were collected for the following assays. (a) LIMS2 protein levels in different groups were determined using western blotting assay. (b) CCK-8 assay and (d) Edu staining were applied for cell growth detection. (d, e) Cell migration and invasion capacities were tested with the transwell chambers (n = 3, ?p < 0.05, ??p < 0.01, ???p < 0.001, and LIMS2 group vs. NC group).
Fig 2: Enrichment analysis of LIMS2 and its correlated genes. (a) GO and (b) KEGG analysis of the LIMS2 and its correlated genes.
Fig 3: Low expression of LIMS2 was linked to poor prognosis in OS. The relationships between LIMS2 expression levels and (a) the overall survival and (b) the disease-free survival rates of patients with OS were evaluated using the GEPIA database.
Fig 4: Bioinformatics analysis of the expression and methylation levels of LIMS2 in OS. (a) LIMS2 expressions in different kinds of cancers were assessed using the GEPIA database. (b) LIMS2 expression in sarcoma was assessed by UALCAN database. (c) LIMS2 expression in normal and tumor tissues was evaluated from the GEO (GSE42352). (d) The methylation levels of LIMS2 in sarcoma tissues and normal tissues were analyzed using the ualcan database. (e) CCLE database was applied to assess the methylation levels of LIMS2 in OS cells.
Fig 5: LIMS2 expression was declined in OS cells. (a) qRT-PCR and (b,cC) western blotting assays were applied to assess the mRNA and protein levels of LIMS2 in normal hFOB 1.19 cells and OS cell lines (U-2OS, MG-63, Saos-2, and MNNG/HOS). (d) MS-PCR was applied to detect the methylation levels of LIMS2 in hFOB 1.19 cells and OS cell lines (U-2OS, MG-63, Saos-2, and MNNG/HOS) (n = 3, ?p < 0.05, and ???p < 0.001).
Supplier Page from Abcam for Anti-PINCH-2 antibody